Researchers from the Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit at the University of the Witwatersrand (Wits) have played a leading role in an international phase 1/2 clinical trial demonstrating the safety and immunogenicity of an investigational maternal vaccine against Group B Streptococcus (GBS)—a major cause of life-threatening infections in newborns worldwide. The findings have been published in Nature Medicine.
This article was originally published on MedicalXpress.com
